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reproduces known associations, and
provides rich opportunities for research.
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THE BIGGER PICTURE The engagement of participants in the research process and broad availability of
data to diverse researchers are essential elements in building precision medicine equitably available for
all. The NIH has established the ambitious All of Us Research Program to build one of the most diverse
health databases in history with tools to support research to improve human health. Here, we present
the initial launch of the Researcher Workbench with data types including surveys, physical measurements,
and electronic health record data with validation studies to support researcher use of this novel platform.
Broad access for researchers to data like these is a critical step in returning value to participants seeking
to support the advancement of precision medicine and improved health for all.

Production: Data science output is validated, understood,
and regularly used for multiple domains/platforms

SUMMARY

The All of Us Research Program seeks to engage at least one million diverse participants to advance precision medicine and improve human health. We describe here the cloud-based Researcher Workbench that
uses a data passport model to democratize access to analytical tools and participant information including
survey, physical measurement, and electronic health record (EHR) data. We also present validation study
findings for several common complex diseases to demonstrate use of this novel platform in 315,000 participants, 78% of whom are from groups historically underrepresented in biomedical research, including 49%
self-reporting non-White races. Replication findings include medication usage pattern differences by race
in depression and type 2 diabetes, validation of known cancer associations with smoking, and calculation
of cardiovascular risk scores by reported race effects. The cloud-based Researcher Workbench represents
an important advance in enabling secure access for a broad range of researchers to this large resource and
analytical tools.
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INTRODUCTION
The NIH’s All of Us Research Program (All of Us) is a longitudinal
cohort study aimed at advancing precision medicine and
improving human health through partnering with one million or
more diverse participants across the United States.1 Informed
by the success of prospective longitudinal cohorts and the more
recent research use of electronic health records (EHRs), All of Us
combines participant-derived information from surveys (participant-provided information [PPI]) and physical measurements
(PMs), EHRs, biospecimens, wearables, and planned links to
external data sources to allow for both active and passive data
collection; participants may also consent to recontact.2 Whereas
a conventional biorepository design delivers data to investigators,
the All of Us program has adopted a different infrastructure,
described here, to ‘‘bring researchers to the data’’ in a cloudbased environment.3 This approach should both enhance data
storage and security, as well as provide facile access to data
and analysis tools to a broad range of researchers including those
in computationally underdeveloped environments. This infrastructure will enable both hypothesis-generating approaches as well as
traditional hypothesis testing by researchers with diverse interests
and capabilities, with the ultimate goal of improving individualized
care and outcomes.
All of Us launched national recruitment in May 2018 and as of
June 2021 had enrolled over 387,000 participants, of whom
295,000 had provided biospecimens and survey data. Recruitment is accomplished by a large multi-disciplinary consortium,
2 Patterns 3, 100570, August 12, 2022

with enrollment centers in varied settings including health provider organizations and community partners. Specific emphasis
in the program has been placed on recruiting participants from
groups that have been historically underrepresented in biomedical research (UBR), and as of May 2021, over 75% of participants are identified as UBR including racial and ethnic groups,
income levels, educational attainment, rural living area, sexual
and gender minorities, and individuals with disabilities.4 All of
Us is committed to engaging participants longitudinally, ensuring
access to their own data and to results of research, including
support for a participant partnership program to inform the direction of the program and research processes.1
The cloud-based Researcher Workbench5 described here has
been developed to democratize access for researchers by eliminating requirements for large local infrastructure and to enhance
data security by minimizing individual data copies.6 The platform
is designed to meet the FAIR principles of research—Findable,
Accessible, Interoperable, and Reusable—developed to address
concerns about the reuse of scholarly data on behalf of a diverse
set of stakeholders representing academia, industry, funding
agencies, and scholarly publishers.7 Additionally, All of Us has
developed policies to lower barriers to data access necessitated
by human subjects research review by removing known identifiers and applying privacy preserving methodology enabling a
‘‘passport model’’ that grants broad access to the non-human
subjects research dataset that was approved by the program
institutional review board instead of burdening researchers with
completing the conventional project-by-project mode of review.
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Figure 1. Overview of data types included in
the beta-release curated data repository
(A) Growth trajectory of participant data types after
enrollment. Survey part 1 (green) includes ‘‘the Basics,’’ ‘‘Lifestyle,’’ and ‘‘Overall Health’’ surveys;
survey part 2 (pink) includes ‘‘Personal Medical
History,’’ ‘‘Health Care Access and Utilization,’’ and
‘‘Family Medical History.’’ Physical measurement
accrual is shown in red, and the COVID-19 Participant Experience (COPE) survey is shown in purple.
Note that the flattening is artificial due to the random
date shift introduced to protect participant privacy.
(B) Historical availability of participants’ electronic
health record (EHR), survey, and device data.

have been made available in the
Researcher Workbench for replication
and reuse.
RESULTS

Currently, researchers are approved from institutions that have
signed a data-use agreement and after completing ethics training
by using their eRA Commons ID.
All of Us has adopted a philosophy of early, iterative data
release and the establishment of demonstration projects with
the goal of evaluating the quality, usefulness, validity, and diversity of the research dataset and platform.1,8 A particular
challenge for All of Us, compared with other large cohorts
such as the UK Biobank and the Million Veterans Program, is
harmonizing many data sources, necessitating demonstration
of data validity and utility.9,10 A core value of All of Us is to
ensure equal access to the data by researchers; therefore,
demonstration projects presented here were not designed to
make significant biological discoveries but rather to describe
the cohort and validate the Researcher Workbench structure
by replicating previous findings. Here, we describe the demographics of the first 315,007 participants and the results of
demonstration projects investigating treatment pathways of
diabetes and depression medication, the relation of smoking
to cancer, and calculation of baseline cardiovascular disease
risk scores using the data and tools in the All of Us Researcher
Workbench. We also estimated compute costs for these analyses. All methods, cohorts used, and relevant analytical code

Demographics of the dataset
The beta launch of the Researcher Workbench includes data from 315,007 total
participants. Figure 1A displays an overview of the data types available, including
PMs obtained in person, surveys
completed electronically, and EHRs from
enrolling partners. In the dataset analyzed,
personal identifiers were removed, and a
random backward date shift (1–365 days)
was introduced; researchers may access
non-deidentified datasets only with specific approvals. The date shift causes
some survey data to appear before the
start of program enrollment.
By design, all participants have data from the first of the part 1
surveys, ‘‘the Basics’’ survey, which must be completed before
participants are eligible to complete other steps in the All of Us
protocol. The second two surveys, ‘‘Overall Health’’ and ‘‘Lifestyle,’’ have 307,756 and 306,316 participant responses,
respectively. The part 2 surveys distributed 90 days after enrollment, ‘‘Healthcare Access & Utilization,’’ ‘‘Family History,’’ and
‘‘Personal Medical History,’’ have 98,541, 91,695, and 89,261
participant responses, respectively. The most recently launched
survey, COVID-19 Participant Experience (COPE), has 62,664
responses, and 8,435 participants have data from a Fitbit device.
Of those with any survey response, 263,425 have at least one PM
recorded, and 203,813 have any EHR data included. The total
number of participants who have any survey response, PM,
and EHR data is 196,709. Additional breakdowns of individual
data types are shown in Figure S1. Figure 1B shows the historical
availability of EHR and Fitbit data by structured domains of
information.
Demographic information included in the dataset is extracted
from ‘‘the Basics’’ survey response. Figure 2 details additional
survey responses into the program definitions of participant status as UBR. Notably, 49% of participants identified with a population other than White alone, and 13% of participants identified
Patterns 3, 100570, August 12, 2022 3
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Figure 2. UBR metrics
Depiction of the proportion of participants that are
underrepresented in biomedical research (UBR)
based on program definitions. A participant is
included in the overall category if they meet at least
one criterion among the race/ethnicity, income, age,
sexual orientation, education, gender identity, and
sex at birth designations. The sexual and gender
minorities category shows aggregates of any
participant with a UBR response to questions on
sexual orientation or gender identity or sex at birth.
GED, General Education Development (i.e., high
school diploma or equivalent).

with a sexual or gender minority group. Overall, 78% of participants were included in at least one UBR category. Additional
breakdowns are shown in Figure S2.
Treatment-pathway visualization
Depression and type 2 diabetes (T2D) are common diseases for
which multiple medications are used. The order of treatment(s)
prescribed after common disease diagnosis was determined to
demonstrate medication mapping and use of hierarchies in the
dataset. The numbers of participants meeting inclusion criteria
to map treatment pathways were 19,206 total participants with
T2D and 29,337 with depression. The number of participants
contributed by individual consortium EHR sites are shown in
Table S1. The treatment-pathway visualizations are shown in
Figures 3A–3D, and the percentage of usage of most common
medications by year is in Figures 3E and 3F, with separate
counts for White and non-White participants. The innermost circle represents the first medication class prescribed, and the circles expanding outward are the second and third medication
classes occurring in the EHR after diagnosis. The most common
first medication classes were biguanides for T2D and selective
serotonin-reuptake inhibitors for depression in both White and
non-White participants. However, the proportion of those
treated first with the most common medication prescribed for
both T2D and depression differed between White and non-White
participants (p < 0.01), and the order of subsequent medication
use differs as well. These results replicated published
analyses.11
Cancer phenome-wide association with smoking study
A cancer phenome-wide association study (PheWAS) was
performed to determine whether known associations with
smoking could be replicated and to compare effect sizes
of smoking exposure gathered from EHR billing codes with
smoking exposure determined from survey data.12,13 A total
of 32,755 participants were identified as EHR ever smokers
and 145,844 as EHR never smokers using billing codes. The
4 Patterns 3, 100570, August 12, 2022

survey responses identified 122,524 participants as ever smokers, 55,986 participants as current smokers, and 175,809
never smokers. In both analyses using
PPI data, the PPI never-smoking group
was used as the comparison group. The
overlap of these participants is shown
in Table S2. The results of the cancer
phenome-wide associations for EHR ever smoking and survey
ever smoking are shown in Figures 4A and 4B. Effect sizes for
the results of the top five EHR non-protective and protective
phenome-wide significant cancer associations matched to
their phenome-wide significant result from the survey eversmoking cancer PheWAS are shown in Table S3. An
expanded results list for each is included in Table S8. The
top cancer phenotypes for which ever smoking was a risk
include respiratory cancers and cervical cancer, both known
associations. Smoking was protective against cutaneousrelated neoplastic outcomes, which has also been previously
reported.14–16 A comparison between the effect sizes seen
in EHR results versus survey ever smokers is shown in Figure 4C. 20% of the EHR effect sizes were statistically significantly higher than the ever-smoking effects. The comparison
of effect sizes seen in All of Us data with literature is shown
in Figure 4D.17 For 12 out of 15 of the phenotypes, there
was at least one cancer PheWAS result whose confidence interval overlapped with the confidence interval reported in the
corresponding meta-analysis.
Cardiovascular disease risk calculation
A number of tools have been developed to calculate risk for
atherosclerotic cardiovascular disease (ASCVD). Many of these
incorporate race in their risk estimates. In this analysis, we estimated ASCVD risk using the American College of Cardiology/
American Heart Association (ACC/AHA) 2013 Pooled Cohort
Equations.18 Participants were included if aged 40–79, and the
following model parameters were available from the EHR data:
total cholesterol (TC), high-density lipoprotein cholesterol
(HDL), systolic blood pressure (SBP), and hypertension treatment status, diabetes status, and no evidence of existing
ASCVD on enrollment. There were 49,982 participants with all
parameters necessary for calculation of the ASCVD risk score
prior to observation of any cardiovascular event. Among these
participants, 32,148 (64.3%) were assigned female sex at birth,
9,331 (18.7%) were African American, 10,564 (21.1%) had other
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Figure 3. Medication sequencing for participants who have diabetes and depression grouped by race
(A) Anti-diabetic medication sequences for White participants.
(B) Anti-diabetic medication sequences for non-White participants.
(C) Antidepressant medication sequences for White participants.
(D) Antidepressant medication sequences for non-White participants.
(E) Percentage of White participants who were prescribed one medication that is the most common one from years 2000–2018.
(F) Percentage of non-White participants who were prescribed one medication that is the most common one from years 2000–2018. The difference in counts of
first anti-diabetic in (A) and (B) and the counts of first antidepressants in (C) and (D) for each medication between White and non-White participants was significant
(p by chi-square was <0.05).

a single or two or more races assigned to ‘‘other’’ for score calculation, 30,087 (60.1%) were White, and 6,603 (13.2%) were
smokers. Table S4 summarizes demographic information for
All of Us participants, participants who have any EHR data,
and participants with sufficient data to calculate risk scores.
The mean age of participants with calculated scores was 57.3
(SD ± 9.9) years, and the mean SBP was 127.4 (SD ± 14.0). There
were 8,821 (16.4%) participants who had the onset of new CVD
within 10 years of measurement.
Across all three groups, scores were significantly different
(p < 0.001) by race (Figure 5A; Tables S5 and S6). In pairwise
comparison, risk scores for White and other race participants
were lower than for African American race (p < 0.001) in both

scores calculated at any time and those calculated within a
year of enrollment. Other race participant scores were significantly lower than White participants in the scores at any time
overall and within a year of enrollment (p < 0.001). We compared
the percentage of All of Us participants at each ASCVD risk
threshold to the US population scores as estimated previously.18
The trend in the percentages of participants by risk and race
groups in seven ASCVD score groups is similar in both studies,
as shown in Figures 5B and 5C.
Cost and sharing of analytic methods and code
The total compute cost for all analyses, from the beginning to the
submission of this paper, was approximately $96. Table S7
Patterns 3, 100570, August 12, 2022 5
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Figure 4. Cancer PheWAS ever-smoking EHR and survey comparison
(A) Manhattan plot for Cancer PheWAS using EHR ever smoking as exposure. Results are the log10 (p value) of the corresponding logistic regression adjusted
for age at last relevant EHR code, sex at birth, race and ethnicity from surveys, EHR length, and number of unique billing codes per record. Up arrows indicate
non-protective associations, and down arrows indicate protective ones. Phenotype labels are given to the top ten phenotypes based on magnitude of effect size
for both protective and non-protective effects.
(B) Manhattan plot for cancer PheWAS using survey ever smoking as exposure, with the same presentations as (A).
(C) Comparison of survey smoking-regression estimates (colored in blue) to EHR smoking-regression estimates (colored in red) for cancer outcomes.
(D) PheWAS EHR ever-smoking (dark blue) and survey ever-smoking (light blue) effect sizes and confidence intervals compared with published meta-analyses
(orange). Estimates are presented on the natural log ratio scale (odds ratio [OR] or risk ratio [RR]). Estimates below the horizontal line represent protective effects,
and estimates above the line represent non-protective effects. Each meta-analysis plot point shape represents whether the effect size from the literature was an
OR, HR, or an RR, recognizing that RR and ORs are not directly comparable except in the case of rare disease.

indicates the rates and cost of individual analyses. All analyses
presented have been made available within the Featured Workspaces section of the Researcher Workbench that permits researchers to view and duplicate code for replication of analyses
or adaptation for their own use.
DISCUSSION
A core principle of the All of Us program is to provide data to researchers quickly, in a manner that is transparent to participants.1 The initial launch of the cloud-based Researcher Workbench was in May 2020, 2 years after the national launch of
participant enrollment, and includes robust security practices
for participant protection.19 Currently, access is provided to all
researchers whose institutions sign a data-access agreement;
6 Patterns 3, 100570, August 12, 2022

the approvals are at US academic institutions and other health
research non-profits, with future plans to expand access to researchers in industry and the international community in 2022
as well as to create paths for citizen scientists in the future.
The cloud-based analysis platform not only enhances data security but also enables ready sharing and reproduction of research
findings; all code of demonstrations described here can be
copied and replicated from the Featured Workspaces in the
Researcher Workbench. Additionally, the use of the Observational Medical Outcomes Partnership (OMOP) Common
Data Model, supported by a broad coalition of users, sets a foundation for interoperability with other cohorts made realistic by
cloud-based sharing of code for replication and reuse.20 By
making computational tools available with the data, All of Us expands researcher access to those who do not have resources to

ll
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store and compute on large datasets and provides a foundation
for the future addition of storage-intensive data types such
as whole-genome sequences and digital health data streams.
To increase transparency of research using the All of Us data
to the public, including study participants, the public
ResearchHub website includes a description of each workspace
within the Researcher Workbench and a directory of all researchers approved for access. All of Us is also committed to
the direct return of results to participants, including engagement
with participant ambassadors in the policy process21 who found
that the need for demonstration of responsible curation and
research use was important to earn and retain participants’ trust
and show how their data might be used to further health
research.
The demonstration projects described here, together with the
availability of the analysis code for researcher reuse, show the
potential of the cohort for a variety of research purposes. For
example, the description of medication sequencing in common
complex diseases such as T2D and depression speaks to the
validity of the data aggregated from over 30 individual healthcare facilities in showing expected treatment patterns. As
with all these examples, the code needed to reproduce these
results is provided, giving researchers the foundation to extract
medications from the data model and extrapolate them to classes using a common medication ontology. Other discoveries
may be advanced in this growing dataset, with the entire
PheWAS package now available in the Researcher Workbench
for researcher reuse and new hypothesis generation. Finally,
the calculation of the ASCVD pooled risk scores also shows
the feasibility of detailed derivation of multiple data elements
required for this estimation. While this ASCVD calculation,
which included historical EHR data, likely demonstrates survivor bias in those included, the replication of known race relationships to established risk models and ongoing ability to
monitor should provide valuable baseline data for decades
to come.
The projects described here aim to replicate prior findings and
show how the dataset can be used, without preempting significant discoveries. We provide example visualizations of general
cohort characteristics to illustrate the heterogeneity of available
data types and the diversity of the cohort. EHR data are currently
available for roughly two-thirds of the cohort at this time; we
expect that this proportion will grow over time. All surveys are
now available at enrollment, and implementation trials are underway to increase response rates further. The program has
committed to improving survey completion rates including
development of a reassessment module to monitor outcomes
over time. Nearly 100% of participants with data in the
Researcher Workbench have a biospecimen available, and generation of genomic data on this cohort has begun. Thus, given
the high proportion (over 75%) of participants included from
groups traditionally UBR, this cohort will provide the foundation
for genome-based studies in minority populations as well as with
ongoing collection of EHR outcomes data be uniquely well suited
to studying health disparities.22
These replication projects highlight the value of EHR data obtained from many healthcare partners merged with direct participant data from measurements and surveys and made available
in a privacy-sensitive, secure, powerful compute environment.

OPEN ACCESS

Researcher Workbench support services also include an interactive monitored user forum to communicate with the program and
other researchers, as well as an integrated help desk ticketing
system to support researchers and gather feedback for the program. The code for the projects presented here and others
completed will also be made directly available to researchers
in the Featured Workspaces section of the Researcher Workbench for replication and reuse,5 benefitting researchers by
saving work to generate new code when existing approaches
can be adapted, as well as returning value to participants in fulfilling FAIR principles and elevating reproducibility and validity of
findings.
Because participants contribute data in many different ways,
the cohort enables prospective, retrospective, cross-sectional,
and nested case-control analyses. The coronavirus 2019
(COVID-19) crisis occurring concurrently with the planned launch
of the Researcher Workbench provided All of Us the opportunity
to rapidly adapt and serve the emergent need for COVID-19relevant research. In-person enrollment of participants paused,
and the consortium pivoted to use biospecimens for antibody
testing to localize early spread of the virus, developed new surveys that align with other cohorts to gather data directly from
participants, and worked to ensure appropriate capture of
COVID-19-relevant EHR data.23 While the current curation timeline and model did not allow real-time provision of pandemicrelated data to researchers, both the COVID-19 survey data
and COVID-19 serology data are now available in the Researcher
Workbench for retrospective analyses of the health outcomes in
the cohort less than 6 months from generation.
Limitations of the beta-launch platform presented here include
access that is more restricted than the planned full release with
expanded access options planned in 2022 to reach industry
and international researchers. Finding the balance of privacy, security, and sharing is ongoing, and to fulfill the pledge to protect
participants, this limitation has given the program an opportunity
to learn how to share widely and wisely. Additional risk in this
limited launch is paucity of data specific for researchers focused
on health disparities and minority health given the generalizations
required for privacy at this time and a lack of a comprehensive
assessment of social determinants of health, which will be
captured in the next survey that will be offered to participants.
The program also plans to release these data in 2022, including
more granular demographic information and the exact dates of
events without the date shift included in the current release.
The requirements of knowledge of Python 3 or R to perform analyses in the Researcher Workbench may exclude some researchers unfamiliar with these methods. Currently, batch workflow is not available, and computational ability to deal with larger
datasets will be required when genomics and other wearable
data expand to enable deep-learning techniques; these capabilities are also slated for release in 2022. Questions asked during
the researcher registration process and workspace descriptions
are providing valuable data to the program regarding diversity of
research topics as well as of the researcher community. Because
we have prioritized early, iterative data release and the speed of
sharing this dataset, some data types are limited. Also, the date
shift introduced to decrease identifiability of participants by disallowing comparison of rare events found with actual dates in
publicly available reporting makes seasonal and cross-sectional
Patterns 3, 100570, August 12, 2022 7
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research in relation to major events impossible. The response
rate of later-release surveys is low but increasing with earlier delivery of all surveys and focused efforts at maintaining ongoing
engagement with the program. Heterogeneity of EHR data,
including needs for harmonization and data missingness, can
hinder studies, and specific efforts are focused on improving
conformance to the data model and completeness from existing
sites, as well as exploring newer direct links such as Apple Health
Record linkage, Sync for Science, and other Fast Health Interoperability Resource (FHIR)-based efforts allowing for participant
health record data donation.24–26 Additionally, the calculations
to balance reidentification risk will be updated as the cohort
grows, which will likely allow for fewer generalizations in future
data releases, allowing more granular inspection of groups traditionally underrepresented in research. Finally, as many other
large cohorts are developing, including the UK Biobank and the
Million Veteran Program, learning to interoperate and jointly
analyze data will be paramount. Notably, All of Us, unlike other
large resources, has an explicit commitment to return data to participants. The opportunities to develop new methodologies to
handle data at scale are greater than ever, and the low-cost,
secure Researcher Workbench platform fulfills a great unmet
need to advance precision medicine research including future implementation of machine-learning approaches.27,28
While significant progress has been done to allow for the safe
sharing of All of Us data with the research community, many
challenges lie ahead in navigating the future of All of Us research,
including ensuring ongoing engagement with diverse participants, reduction of data missingness, and rapid expansion of
data types including digital health technology, genomics, and
external data linkages. The beta launch of the Researcher Workbench begins a process of iterative improvement, fulfilling the
goal of providing data to researchers early and often. The All of
Us Research Program looks forward to incorporating feedback
from the research community on this initial release of data
and tools.
The initial release of the All of Us Research Program data reflects diverse participants with broad information, reproduces
known associations, and provides rich opportunities for research.
The dataset and tools form a strong foundation for cohort growth
and future research advancing the program mission to improve
human health and advance precision medicine.
EXPERIMENTAL PROCEDURES

Figure 5. Baseline cardiovascular disease risk calculations
(A) Baseline 10 year ASCVD cardiovascular disease risk calculations (%). A histogram of the cardiovascular disease risk score for participants with necessary measurements grouped by race group into White, African American, and other. The difference among the cardiovascular risk scores across the three race groups was
statistically significant (p value for the Kruskal-Wallis H test was 0). Mann-Whitney
p value was <0.001 when comparing the risk scores for White versus African
American participants, other versus African American, and White versus other.
(B) Comparing the percentage of All of Us participants to the US population in
each ASCVD risk category as published in ACC/AHA guidelines. The risk score
for US population was calculated by applying the pooled cohort equations (i.e.,
ASCVD score) to the National Health and Nutrition Examinations Surveys.
(C) Comparing the percentage of All of Us participants in each race group with
the US population in each ASCVD risk category as published in ACC/AHA
guidelines. The risk score for US population was calculated by applying the
pooled cohort equations (i.e., ASCVD score) to the National Health and Nutrition Examinations Surveys.
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Resource availability
Lead contact
Requests for additional information about the findings presented in this study
may be directed to the lead author, Andrea Ramirez (andrea.ramirez@nih.gov).
Requests for information about the All of Us Researcher Workbench platform,
including access, may be directed to the All of Us Researcher Workbench support team (support@researchallofus.org). For more information about the All of
Us Research Program data and tools, please visit https://www.researchallofus.
org/.
Materials availability
Study materials are made available through the Researcher Workbench at
https://researchallofus.org.
Data and code availability
Data and code used in this study are available as a featured workspace to
registered researchers of the All of Us Researcher Workbench. For information
about access, please visit https://www.researchallofus.org/.
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Methods
Protocol
The goals, recruitment methods and sites, and scientific rationale for All of Us
have been described previously.1 Participants consent to the study and authorize the sharing of EHRs through an online portal or smartphone application,
after which they can answer health surveys, share digital health data (such
as any Fitbit model and Apple HealthKit), and can view their study information.
Through in-person visits, participants are invited to contribute biospecimens
and undergo PMs including systolic and diastolic blood pressure, height,
weight, heart rate, waist and hip measurement, wheelchair use, and current
pregnancy status. Structured EHR data are transferred from enrolling sites
at least once per quarter.
Data curation and privacy methodology
Surveys, PM, and EHR are mapped to the OMOP common data model v.5.2
maintained by the Observational Health Data Sciences and Informatics
(OHDSI) collaborative.20 Where the model does not support necessary concepts, custom concepts are added in collaboration with the OHDSI community, linked to existing concepts where possible, and documented in the
open-source Athena resource, a repository of vocabularies used in OMOP
and supported by Odysseus Data Services.29 Participants were included in
the beta-launch curated data repository (CDR) if they responded to at least
the first survey, ‘‘the Basics.’’ To protect participant privacy, a series of data
transformations were applied including data suppression of codes with a
high risk of identification such as military status; generalization of categories
including age, sex at birth, gender identity, sexual orientation, and race; and
date shifting by a random number of days from 1 to 365 implemented consistently across each participant record, causing some data to appear to have
accrued before program start. General conformance rules are applied to
meet the standard conventions of the OMOP data model including dropping
invalid dates and extreme values, resulting in a base version of the CDR. Additional cleaning steps for selected lab data (from EHRs) and PMs were performed to standardize units and values resulting in the processed CDR, on
which the analyses presented here were performed. Documentation on privacy implementation and creation of the CDR is available in the Research
Hub at www.researchallofus.org and in the All of Us Registered Tier CDR
Data Dictionary.30
Platform
The dataset was accessed through the All of Us Researcher Workbench,
a cloud-based analytic platform custom built by the program for approved
researchers. The Workbench is built on top of the Terra platform (terra.bio),
which is also utilized for a number of other NIH-funded studies including
the National Cancer Institute (NCI Cloud Resources), the National Heart,
Lung, and Blood (NHLBI) BioData Catalyst, and the National Human
Genome Research Institute (NHGRI) AnVIL. The Workbench exceeds Federal Information Security Management Act (FISMA) moderate security standards and undergoes routine security testing.31 The All of Us Researcher
Workbench platform includes project-specific spaces, termed workspaces,
featuring a description of the project and permitting sharing among teams
of collaborators. Workspaces include access to graphical ‘‘point and click’’
interface tools to select participants (a ‘‘cohort builder’’) using a variety of
Boolean criteria across data types and selection of data elements for analysis. Analyses are currently performed using Jupyter Notebooks.32 The
notebooks currently enable use of saved datasets and direct query using
R and Python 3 programming languages. Access to the Researcher
Workbench and data are free. Compute and storage accrue usage cost.
The Researcher Workbench uses Google Compute Engine for computational resources in the cloud and Google Cloud Storage for storage in
the cloud.
Access
All researchers who access the data for analyses are currently authorized and
approved via a 6-step process that includes registration, affiliation with an
institution that has completed a Data Use and Registration Agreement, identity
verification via login.gov, completion of ethics training, and attestation to a
data use agreement. Approval to use the dataset for the specified demonstration projects was obtained from the All of Us Institutional Review Board. Results reported are in compliance with the All of Us Data and Statistics Dissemination Policy disallowing disclosure of group counts under 20 to protect
participant privacy.33
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Descriptive visualizations
The age displayed reflects the age when the CDR version used in this report
was generated in the summer of 2020. Presence of a data-type survey, PM,
or EHR was counted if at least one observation was present within each category. To assess race and ethnicity, participants were asked ‘‘Which categories
describe you? Select all that apply. Note, you may select more than one
group’’ in the ‘‘the Basics’’ survey. Responses were mapped to the race variable in the OMOP Person table directly for the responses White, Asian, and
Black, African American, or African, and responses Middle Eastern or North African and Native Hawaiian or other Pacific Islander were generalized to ‘‘Other
single population’’.
Currently, all participants responding American Indian or Alaska Native have
been removed from the CDR, as All of Us goes through official consultation
with tribal leaders on the research use of data. Participants choosing any
two of the categories were labeled ‘‘More than one population.’’ Skipped
questions were omitted, and the responses ‘‘None of these fully describe
me’’ and ‘‘I prefer not to answer’’ or non-responses to these categories
were individually mapped in the data model and grouped as ‘‘Not specified’’
for visualization for the analyses presented here. The ‘‘Not specified’’ group
included participants who chose Hispanic, Latino, or Spanish. This response
was mapped to the ethnicity variable, allowing reflection of both race and Hispanic ethnicity. Program designations of status as UBR were adapted to data
available in the CDR.34
Treatment-pathway visualization
The order of treatment prescribed after common disease diagnosis was determined for T2D and depression to demonstrate medication mapping and use of
hierarchies in the OMOP common data model. For each condition, the time of
earliest diagnosis was identified, and medications were extracted using the
OMOP hierarchy as in the previously published work. Medications were then
grouped into generalized classes based on their main ingredient using the
anatomical therapeutic chemical (ATC) classification.35 Participants were
included if their first medication related to the disease was prescribed after
the earliest diagnosis code for that disease, they had two or more diagnosis
codes for the disease, and they had at least 3 years of medication records
with at least a single structured occurrence of the drug. We determined the
number of participants whose monotherapy was the most common first medication in any given year between 2000 and 2016. Each of these analyses was
performed separately on the participants identified as White and compared
with those included in any non-White response. A chi-square test was used
to compare medication sequences between races.
Phenome-wide association of cancer with smoking study
To define ever-smoking exposure from EHR data (EHR ever smoker), we identified all participants with at least two instances on separate calendar days of
ICD-9-CM codes 305.1* (tobacco use disorder), 649.0* (tobacco use disorder
complicating pregnancy, childbirth, or the puerperium), V15.82 (history of
tobacco use), and 989.84 (toxic effect of tobacco) or ICD-10-CM codes
Z72.0 (tobacco Use), Z71.6 (tobacco abuse counseling), O99.33* (tobacco
use disorder complicating pregnancy, childbirth, and the puerperium),
Z87.891 (personal history of nicotine dependence), F17.2* (nicotine dependence) excluding F17.22* (nicotine Dependence, chewing tobacco), and
T65.2* (Toxic effect of tobacco and nicotine) excluding T65.21* (toxic effect
of chewing tobacco). To define never smokers from EHR data (EHR never
smoker), zero occurrences of the defining codes above and at least one other
ICD-9-CM or ICD-10-CM code that was not T65.21* or F17.22* was required.
To define smoking exposure from survey data (survey ever smoker), the ‘‘Lifestyle’’ survey responses were used. Specifically, the response to ‘‘Have you
smoked at least 100 cigarettes in your entire life?’’ was used to include participants as a survey ever smoker, and the branching logic question ‘‘Do you now
smoke cigarettes every day, some days, or not at all?’’ with the response
‘‘Every day’’ was used to designate current smokers. Conversely, participants
answering ‘‘No’’ to the 100-cigarettes question were included as survey never
smokers, and participants skipping the question were excluded. The logistic
regression model used in the PheWAS analyses was implemented using the
statsmodels Python module, optimized for compute efficiency, and made flexible for reuse with variable inputs. The analysis was corrected for age at last
code occurrence, sex at birth, race and ethnicity as generalized from survey
responses, EHR length as reflected by time between first and last billing
code, and unique billing codes per record.
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To compare the phenome-wide associated effects found in the respective
PheWAS analyses to prior results, we searched PubMed for meta-analyses
that produced effects comparable to the odds ratios produced by the logistic
regressions. We first searched PubMed for all meta-analyses related to
smoking using the R package easyPubMed and query "(tobacco[TI] OR
smoking[TI]) AND meta-analysis[All Fields]") and found 1,840 results.
Computable restrictions were then applied including limitation to active
smoking-exposed individuals and excluding genetic and smoking-cessation
studies, resulting in 538 studies. Manual review then included only those titles with phenotypes represented in the PheCode ontology.36–38 We then
restricted to only those meta-analyses that could be matched with a phenome-wide significant result from at least one of the PheWAS analyses
and a comparable effect, finding 51 ever-smoking meta-analyses across
38 unique phenotypes, of which 15 had a phenome-wide significant result
that was related to an oncologic outcome with ever-smoking exposure,
among phenotypes where there was a PheWAS result in both EHR and
PPI. Results were plotted to compare with All of Us results for EHR and survey ever-smoking phenotypes.
Cardiovascular disease risk calculation
Ten-year ASCVD risk was calculated according to the 2013 Pooled Cohort
Equations.18 Participants were included if aged 40–79, and the following
EHR data were available: TC, HDL, SBP, and treatment status, diabetes status, and no evidence of existing ASCVD. We used the gender that was assigned to the participants at birth. The codes used to identify ASCVD outcome,
diabetes, hypertension, and treatment are presented in Table S4. We removed
values outside the valid ranges for the scores: TC 130–320, HDL 20–100, and
SBP 90–200 mm Hg. Measurements were included within 1 year of the most
frequently available variable, SBP. If multiple measures were in the window,
the median was used. Current smoking status was taken from the participants’
survey response within ‘‘Lifestyle’’ branching logic to age started smoking and
age stopped smoking to determine if smoking occurred during the score
calculation. The beta coefficients for African American race were used if the
participant selected only Black, African American, or African and White if the
participant selected only White in ‘‘the Basics’’ survey. Any other response,
multiple responses, or skip was designated as other here, which also uses
the White-race beta coefficients in the ASCVD model. To compare risk scores
among race groups, the Kruskal-Wallis H and Mann-Whitney U non-parametric tests were used. To calculate the optimal risk, we used 170 for TC,
50 for HDL, 110 for SBP, and status as non-smoker, non-hypertensive, and
non-diabetic.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.
patter.2022.100570.
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